Health Information Seeking BehaviorTALK-UNCT07325617
Tracking AI/LLM Literacy and Knowledge in Urology Outpatients (TALK-U)
An observational study of Health Information Seeking Behavior and Anxiety, run by Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
This study is a one-time, questionnaire-based survey of adults attending a urology outpatient clinic. The investigators will examine whether patients who use AI chat tools based on large language models (LLMs), such as ChatGPT, before seeking care differ from non-users in (1) anxiety, (2) satisfaction with the clinic… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Health Information Seeking Behavior, Anxiety
- How many people
- 400 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Jan 2026to 1 Mar 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients (≥18 years) presenting for a first-time visit to the Urology Outpatient Clinic at Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital will be invited to participate during a 2-month recruitment period. Participants who provide written informed consent and can complete a brief questionnaire independently will be enrolled. The study will include both sexes and a broad range of urologic presenting complaints.
Who may be able to join
- Age 18 years or older
- First-time visit to the Urology Outpatient Clinic
- Able to read and write and complete the questionnaire independently
- Able to provide written informed consent
Who cannot join
- Age under 18 years
- Insufficient literacy to understand and complete the questionnaire
- Severe hearing or visual impairment, or a neurological/psychiatric condition that prevents understanding and completing the survey
- Refusal or inability to provide informed consent
- Currently under follow-up for a known urologic condition (i.e., not a first-time urology outpatient visit)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site
Dr.Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital
Ankara, Yenimahalle/Ankara, 06200
Tuncel Uzel, MD, +90 312 336 09 09 ext. 5622, tunceluzelmd@gmail.com
About this study
Official title: The TALK-U Study: Tracking AI/LLM Knowledge and Use in Urology Outpatients and Its Association With Anxiety, Satisfaction, and Health Awareness-A Cross-Sectional Study
This study is a one-time, questionnaire-based survey of adults attending a urology outpatient clinic. The investigators will examine whether patients who use AI chat tools based on large language models (LLMs), such as ChatGPT, before seeking care differ from non-users in (1) anxiety, (2) satisfaction with the clinic visit, and (3) awareness/understanding of their health condition.
Participants who provide written informed consent will complete a brief survey during their clinic visit (about 5-7 minutes). The survey includes a standardized anxiety scale (GAD-7), visual analog scales (0-10) for anxiety before and after the visit, satisfaction, and disease awareness, as well as questions about AI/LLM knowledge and use. Treating clinicians will not have access to participants' survey responses, and participation will not affect clinical care.
Read the detailed description
The TALK-U study is a cross-sectional, observational survey conducted in the urology outpatient clinic of Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital. The primary exposure is self-reported AI/LLM knowledge and use for health information (e.g., whether participants have used ChatGPT or similar tools, frequency, awareness of AI, and purpose of use). The primary outcome is anxiety measured by GAD-7 at the time of the clinic encounter. Secondary outcomes include (i) anxiety assessed on a 0-10 visual analog scale before and after the visit, (ii) outpatient visit satisfaction (0-10 VAS), and (iii) perceived disease awareness/understanding (0-10 VAS).
Eligible adult first-time urology outpatients who can complete the survey independently and provide informed consent will be invited during a 2-month recruitment period. Analyses will compare outcomes between AI/LLM users and non-users and explore associations with age group (<40, 40-60, >60), education level, and urology subspecialty category. Data will be analyzed using appropriate parametric/nonparametric tests depending on distribution, with p < 0.05 considered statistically significant.
- Conditions
- Health Information Seeking Behavior, Anxiety
- Keywords
- Artificial intelligence, Anxiety, ChatGPT, Gemini, Health information seeking, Large language model (LLM), Patient satisfaction
- Medical subject headings
- Anxiety Disorders, Patient Satisfaction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| AI/LLM users | Participants who report prior use of AI chat tools based on large language models (e.g., ChatGPT or similar) for health information before the outpatient urology visit, as assessed by the study questionnaire. | |
| non AI/LLM users | Participants who report no prior use of AI/LLM chat tools (e.g., ChatGPT or similar) for health information before the outpatient urology visit, as assessed by the study questionnaire. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pre-visit Anxiety (VAS 0-10)
Self-rated anxiety on a 0-10 visual analog scale (VAS), where 0 indicates no anxiety and 10 indicates the highest possible anxiety. This measure reflects visit-related state anxiety prior to clinician encounter.
Measured: Day 0 (immediately before the outpatient visit)
Secondary outcomes (3)
Post-visit Anxiety (VAS 0-10)
Self-rated anxiety on a 0-10 VAS (0 = none, 10 = highest).
Measured: Day 0 (immediately after the outpatient visit)
Visit Satisfaction (VAS 0-10)
Self-rated satisfaction with the outpatient visit on a 0-10 VAS (0 = not satisfied at all, 10 = maximum satisfaction).
Measured: Day 0 (immediately after the outpatient visit)
Disease Awareness/Understanding (VAS 0-10)
Self-rated awareness/understanding of one's condition on a 0-10 VAS (0 = none, 10 = complete).
Measured: Day 0 (during the outpatient clinic visit)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jan 2026
- Study start1 Jan 2026 (estimated)
- Primary completion1 Mar 2026 (estimated)
- Study completion1 Mar 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Health Information Seeking BehaviorStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Tuncel Uzel, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07325617
- Sponsor's protocol ID
- 2025-06/98
- Acronym
- TALK-U
- Status last verified
- Dec 2025
- First submitted
- 24 Dec 2025
- Last updated
- 9 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The TALK-U Study: Tracking AI/LLM Knowledge and Use in Urology Outpatients and Its Association With Anxiety, Satisfaction, and Health Awareness-A Cross-Sectional Study
- ClinicalTrials.gov ID
- NCT07325617
- Acronym / sponsor ID
- TALK-U / 2025-06/98
- Conditions
- Health Information Seeking Behavior, Anxiety
- Keywords
- Artificial intelligence, Anxiety, ChatGPT, Gemini, Health information seeking, Large language model (LLM), Patient satisfaction
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research HospitalUniversity, hospital or other
- Study start
- 1 Jan 2026 (estimated)
- Primary completion
- 1 Mar 2026 (estimated)
- Study completion
- 1 Mar 2026 (estimated)
- First posted
- 8 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a one-time, questionnaire-based survey of adults attending a urology outpatient clinic. The investigators will examine whether patients who use AI chat tools based on large language models (LLMs), such as ChatGPT, before seeking care differ from non-users in (1) anxiety, (2) satisfaction with the clinic visit, and (3) awareness/understanding of their health condition.
Participants who provide written informed consent will complete a brief survey during their clinic visit (about 5-7 minutes). The survey includes a standardized anxiety scale (GAD-7), visual analog scales (0-10) for anxiety before and after the visit, satisfaction, and disease awareness, as well as questions about AI/LLM knowledge and use. Treating clinicians will not have access to participants' survey responses, and participation will not affect clinical care.
Detailed description
The TALK-U study is a cross-sectional, observational survey conducted in the urology outpatient clinic of Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital. The primary exposure is self-reported AI/LLM knowledge and use for health information (e.g., whether participants have used ChatGPT or similar tools, frequency, awareness of AI, and purpose of use). The primary outcome is anxiety measured by GAD-7 at the time of the clinic encounter. Secondary outcomes include (i) anxiety assessed on a 0-10 visual analog scale before and after the visit, (ii) outpatient visit satisfaction (0-10 VAS), and (iii) perceived disease awareness/understanding (0-10 VAS).
Eligible adult first-time urology outpatients who can complete the survey independently and provide informed consent will be invited during a 2-month recruitment period. Analyses will compare outcomes between AI/LLM users and non-users and explore associations with age group (<40, 40-60, >60), education level, and urology subspecialty category. Data will be analyzed using appropriate parametric/nonparametric tests depending on distribution, with p < 0.05 considered statistically significant.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| AI/LLM users | – | –Participants who report prior use of AI chat tools based on large language models (e.g., ChatGPT or similar) for health information before the outpatient urology visit, as assessed by the study questionnaire. |
| non AI/LLM users | – | –Participants who report no prior use of AI/LLM chat tools (e.g., ChatGPT or similar) for health information before the outpatient urology visit, as assessed by the study questionnaire. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients (≥18 years) presenting for a first-time visit to the Urology Outpatient Clinic at Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital will be invited to participate during a 2-month recruitment period. Participants who provide written informed consent and can complete a brief questionnaire independently will be enrolled. The study will include both sexes and a broad range of urologic presenting complaints.
Key inclusion criteria (4 listed)
- Age 18 years or older
- First-time visit to the Urology Outpatient Clinic
- Able to read and write and complete the questionnaire independently
- Able to provide written informed consent
Key exclusion criteria (5 listed)
- Age under 18 years
- Insufficient literacy to understand and complete the questionnaire
- Severe hearing or visual impairment, or a neurological/psychiatric condition that prevents understanding and completing the survey
- Refusal or inability to provide informed consent
- Currently under follow-up for a known urologic condition (i.e., not a first-time urology outpatient visit)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Pre-visit Anxiety (VAS 0-10)
Time frame: Day 0 (immediately before the outpatient visit)
Self-rated anxiety on a 0-10 visual analog scale (VAS), where 0 indicates no anxiety and 10 indicates the highest possible anxiety. This measure reflects visit-related state anxiety prior to clinician encounter.
3 secondary outcomes
Post-visit Anxiety (VAS 0-10)
Time frame: Day 0 (immediately after the outpatient visit)
Visit Satisfaction (VAS 0-10)
Time frame: Day 0 (immediately after the outpatient visit)
Disease Awareness/Understanding (VAS 0-10)
Time frame: Day 0 (during the outpatient clinic visit)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jan 2026.
Related trials for Health Information Seeking Behavior
Recruiting
YOUCA App for Parents of Children With Mental Health Issues: A Pilot Study of Usability and Efficacy
Mental Health Help-Seeking, Mental Health Difficulties
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Health Information Seeking Behavior and Anxiety, run by Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 9 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Tuncel Uzel, MD (+90 312 336 09 09 ext. 5622, tunceluzelmd@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pre-visit Anxiety (VAS 0-10) (time frame: Day 0 (immediately before the outpatient visit)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jan 2026.